Vaccitech will combine Oxford University vaccine know-how with the manufacturing expertise of China’s CanSino Biologics in collaboration focused on herpes zoster.
Vaccitech Limited, a UK-based company developing products to treat and prevent multiple infectious diseases and cancer, and CanSino Biologics Inc, a China-based vaccine company focused on prophylactic and therapeutic vaccines, are starting a new collaboration to develop a new vaccine approach to prevent shingles (herpes zoster).
The two companies have signed a Master Collaboration Agreement and initiated their first co-development project under that agreement. Preclinical validation work has already been completed by Vaccitech and Oxford University’s Jenner Institute. GMP manufacturing will be performed by CanSinoBio at their manufacturing facilities in Tianjin, China. Onward development will be joint, with clinical studies to be conducted at sites in both the UK and China.
The companies also plan to explore additional collaborations, combining Vaccitech’s expertise in the research and development of non-replicating viral vaccines with the advanced manufacturing and development capabilities of CanSinoBio, which has already achieved NDA approval for emergency use and national stockpile for its adenoviral vector-based Ebola vaccine in China. Vaccitech has development programmes ongoing in influenza, human papillomavirus, chronic hepatitis B and cancer.
Tom Evans MD, CEO of Vaccitech, said:
“We are thrilled to be working with one of the most advanced manufacturing and vaccine development groups in Asia, and to have such a strong partner in China,”
Xuefeng Yu PhD, Chairman & CEO of CanSinoBio, added:
“This partnership allows us to speed up new vaccine development by leveraging strengths from both parties. We are pleased to collaborate with one of the world’s best vaccine research and development teams.”